The Haematology and Oncology department at GOSH is uniquely set up to treat the rarest and most complex forms of paediatric cancer.
Our overall haematology and oncology survival rates are comparable to the best results internationally. Our ALL studies include the best 5 year survival rates of of any large published series at 94.1%. AML 10 provided the step-change in AML outcome and remains the back-bone of most AML protocols in the world.
The Haematology and Oncology department at GOSH provides a comprehensive service for the diagnosis and management of childhood leukaemia and solid tumours. Our world-leading teams are also able to offer a second opinion service for clinicians from around the world.
The service treats approximately 450 patients each year, accounting for about 28% of national childhood cancer cases. We provide tertiary cancer care along the disease pathway and serve as the principal treatment centre for children and young people diagnosed with a number of different malignant and non-malignant oncological and haematological diagnoses. The clinical service is enhanced by exceptional clinical and translational research, whereby the new findings and benefits discovered in basic research are translated to medical practice more quickly and efficiently – moving developments from the bench to the bedside. For the 5% of patients with the most common form of leukaemia who do not respond to conventional treatment, we launched the world’s first trial of gene therapy to reprogramme children’s immune systems to target leukaemia cells.
Conditions we treat
- Acute lymphoblastic leukaemia
- Acute myeloid leukaemia
- Chronic myelogenous leukaemia
- Juvenile myelomonocytic leukaemia
- Haemophagocytic lymphohistiocytosis
- Non-Hodgkin’s lymphoma